#1
|
|||
|
|||
Ìèêðîêëèçìà ïðè ÄÃÏÆ1 ñò
Óâàæàåìûå äîêòîðà , äîáðîãî âñåì âðåìåíè ñóòîê !
Ïèøó îò èìåíè ñóïðóãà , îí íå âëàäååò íàâûêàìè êîìïüþòåðà . 59 ëåò âåñ 100 ðîñò 170 ñì. Ñ ãèïåðïëàçèåé ïðåäñò æåëåçû íàáëþäàåòñÿ áîëåå 30 ëåò. Ïîñëåäíèé îñìîòð óðîëîãà áûë ñåãîäíÿ. Îáú¸ì æåëåçû ñ 44 óâåëè÷èëñÿ äî 51 ñì 3 çà ãîä . ÏÑÀ 2,2 íã/ìë  îáùåì àíàëèçå êðîâè ãèïîõð àíåìèÿ 1 ñò Íàçíà÷åí àâàäàðò 10 ìåñ è îìíèê 400 ìã 10 ìåñ Ñìóùàåò íàçíà÷åíèå êëèçì ñ îòâàðîì ðîìàøêè è äèìåêñèäîì â ïðÿìóþ êèøêó . Íàñêîëüêî ýòî öåëåñîîáðàçíî ? Áëàãîäàðþ çà âíèìàíèå ê ìîåé òåìå . |
#2
|
||||
|
||||
íåò, åñëè íå õîòèòå íàâðåäèòü åìó - íå äåëàéòå! ïî÷åìó íå ëå÷èòå àíåìèþ? Ïî÷åìó íå êîððåêòèðóåòå åãî îæèðåíèå õîòÿ áû íèçêîóãëåâîäíîé äèåòîé?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
||||
|
||||
åñëè âàì íå ÷óæä èíîñòðàííûé - êðàòêî: îæèðåíèå ñïîñîáñòâóåò ãèïåðïëàçèè (è óêîðà÷èâàåò æèçíü íà 3 ãîäà, åñëè âåñ áóäåò íàðàñòàòü, òî 7...10 ëåò ìèíóñ ê ïðîäîëæèòåëüíîñòè æèçíè)
1) Prior studies consistently showed that increased adiposity is positively associated with radiographically determined prostate volume and enlargement, suggesting that obesity promotes prostate growth. 2) Most studies revealed that obesity increases the risk of clinical benign prostatic hyperplasia by several measures, including the initiation of benign prostatic hyperplasia medical treatment, noncancer prostate surgery, physician diagnosed benign prostatic hyperplasia, histological diagnosis and urinary flow rate. 3) Prior studies demonstrated that obesity increases the risk of lower urinary tract symptoms, as measured by a validated questionnaire. Also, most studies showed that physical activity significantly decreases the risk of benign prostatic hyperplasia.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#4
|
|||
|
|||
Ìèêðîêëèçìà ïðè ÄÃÏÆ 1 ñò
Âàäèì Âàëåðüåâè÷ , áëàãîäàðþ âàñ çà îòâåò.
Âñå ïîíÿëà. Ïðåïàðàò âûáîðà : âåíîôåð â/â ? |
#5
|
||||
|
||||
Àíàëèçû âûëîæèòü ìîæåòå? Êàê ïðàâèëî, ïðè îæèðåíèè æåëåçî âíóòðü ïëîõî óñâàèâàåòñÿ, ÷óòü ëó÷øå - ñ âèòàìèíîì Ñ îäíîâðåìåííî, íî îïòèìàëüíî - â/â âåíîôåð èëè ôåðèíäæåêò (ïîñëåäíèé ìîæíî ââîäèòü ïî 500 ìã çà 1 ðàç), â çàâèñèìîñòè îò òÿæåñòè àíåìèè è íà òàêîé âåñ ìîæåò ïîíàäîáèòñÿ 1000-1500 ìã â ñóììå; íà åãî ðàöèîí ïîâëèÿòü íå ìîæåòå?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#6
|
|||
|
|||
Ýðèòðîöèòû 5,7
Ãåìîãëîáèí 133 MCV 76,9 MCHC 30 MCN 23,3 îñòàëüíîå â íîðìå |
#7
|
|||
|
|||
Íà ðàöèîí âëèÿòü ïûòàþñü
Íî îí òàéêîì ïîêóïàåò êîíôåòû è ïî áóõàíêå õëåáà â äåíü Ïîêàçàëà âàøè îòâåòû , çàäóìàëñÿ Æèòü òî õî÷åòñÿ Áëàãîäàðþ âàñ çà îòâåòû |
#8
|
||||
|
||||
äà, ïîõîæà íà æåëåçîäåôèöèòíóþ, ê ñ÷àñòüþ íå ñèëüíàÿ, 1000 ìã â/â æåëåçà äîëæíî õâàòèòü - êñòàòè æä àíåìèÿ ìîæåò ìåíÿòü âêóñîâûå ïðèñòðàñòèÿ íà óãëåâîäû (ñàõàðíàÿ çàâèñèìîñòü), òàê ÷òî óñïåøíîå ëå÷åíèå ÆÄÀ ìîæåò ñíèçèòü òÿãó ê ë/ó óãëåâîäàì - ñëàäêîìó
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |